SUV39H1 disruption enhances the persistence and anti-tumor efficacy of CD28-costimulated human CAR T cells.

被引：0
|
作者：
Jain, Nayan [1 ]
Zhao, Zeguo [1 ]
Koche, Richard [1 ]
Gozlan, Yosi [2 ]
Brocks, David [2 ]
Raveh-Sadka, Tali [2 ]
Wells, Danny [3 ]
Dobrin, Anton [1 ]
Shi, Yuzhe [1 ]
Lopez, Michael [1 ]
Gunset, Gertrude [1 ]
Sadelain, Michel [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Immunai, Tel Aviv, Israel
[3] Immunai, San Francisco, CA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5583
引用
收藏
页数：1
相关论文
共 50 条
  • [31] CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas (vol 13, 3739, 2022)
    Niborski, Leticia Laura
    Gueguen, Paul
    Ye, Mengliang
    Thiolat, Allan
    Ramos, Rodrigo Nalio
    Caudana, Pamela
    Denizeau, Jordan
    Colombeau, Ludovic
    Rodriguez, Raphael
    Goudot, Christel
    Luccarini, Jean-Michel
    Soude, Anne
    Bournique, Bruno
    Broqua, Pierre
    Pace, Luigia
    Baulande, Sylvain
    Sedlik, Christine
    Quivy, Jean-Pierre
    Almouzni, Genevieve
    Cohen, Jose L.
    Zueva, Elina
    Waterfall, Joshua J.
    Amigorena, Sebastian
    Piaggio, Eliane
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [32] CAR T CELLS UNDERGOING EPIGENETIC REPROGRAMMING BY LOW-DOSE DECITABINE ENHANCES PERSISTENT ANTI-TUMOR EFFICACY IN VIVO
    Wang, Yao
    Han, Weidong
    Tong, Chuan
    Wu, Zhiqianag
    Dai, Hanren
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A460 - A461
  • [33] CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro
    Alishah, Khadijeh
    Birtel, Matthias
    Masoumi, Elham
    Jafarzadeh, Leila
    Mirzaee, Hamid Reza
    Hadjati, Jamshid
    Voss, Ralf-Holger
    Diken, Mustafa
    Asad, Sedighe
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [34] Co-infusion of CAR T cells with aAPCs expressing chemokines and costimulatory ligands enhances the anti-tumor efficacy in mice
    Li, Jing
    Zhou, Weilin
    Li, Dan
    Huang, Yong
    Yang, Xiao
    Jiang, Lin
    Hu, Xiaoyi
    Yang, Jinrong
    Fu, Maorong
    Zhang, Mengxi
    Wang, Fengling
    Li, Jiaqian
    Zhang, Yalan
    Yang, Yuening
    Yan, Feiyang
    Gao, Haozhan
    Wang, Wei
    CANCER LETTERS, 2023, 568
  • [35] CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro
    Khadijeh Alishah
    Matthias Birtel
    Elham Masoumi
    Leila Jafarzadeh
    Hamid Reza Mirzaee
    Jamshid Hadjati
    Ralf-Holger Voss
    Mustafa Diken
    Sedighe Asad
    Journal of Translational Medicine, 19
  • [36] Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer
    Wei Zhang
    Long Shi
    Zhilong Zhao
    Pingping Du
    Xueshuai Ye
    Dongbin Li
    Zhenhua Cai
    Jinsheng Han
    Jianhui Cai
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 911 - 920
  • [37] Disruption of CTLA-4 expression on peripheral blood CD8+T cell enhances anti-tumor efficacy in bladder cancer
    Zhang, Wei
    Shi, Long
    Zhao, Zhilong
    Du, Pingping
    Ye, Xueshuai
    Li, Dongbin
    Cai, Zhenhua
    Han, Jinsheng
    Cai, Jianhui
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (05) : 911 - 920
  • [38] Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8+ T cells
    Mark P. Rubinstein
    Ee Wern Su
    Samantha Suriano
    Colleen A. Cloud
    Kristina Andrijauskaite
    Pravin Kesarwani
    Kristina M. Schwartz
    Katelyn M. Williams
    C. Bryce Johnson
    Mingli Li
    Gina M. Scurti
    Mohamed L. Salem
    Chrystal M. Paulos
    Elizabeth Garrett-Mayer
    Shikhar Mehrotra
    David J. Cole
    Cancer Immunology, Immunotherapy, 2015, 64 : 539 - 549
  • [39] Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8+ T cells
    Rubinstein, Mark P.
    Su, Ee Wern
    Suriano, Samantha
    Cloud, Colleen A.
    Andrijauskaite, Kristina
    Kesarwani, Pravin
    Schwartz, Kristina M.
    Williams, Katelyn M.
    Johnson, C. Bryce
    Li, Mingli
    Scurti, Gina M.
    Salem, Mohamed L.
    Paulos, Chrystal M.
    Garrett-Mayer, Elizabeth
    Mehrotra, Shikhar
    Cole, David J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (05) : 539 - 549
  • [40] LOWERING THE BINDING STRENGTH OF ANTI-CD19 CAR-T CELLS CAN REDUCE TOXICITY BUT AT THE COST OF IN VIVO ANTI-TUMOR EFFICACY
    Doetsch, S.
    Warmuth, L.
    D'Ippolito, E.
    Honold, B.
    Trebo, M.
    Manlik, W.
    Graml, F.
    Stengl, A.
    Schuetz, J.
    Schober, K.
    Schmidt, G.
    Wanisch, A.
    Casucci, M.
    Riddell, S.
    Busch, D.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A13 - A14
12345